<DOC>
	<DOCNO>NCT00003145</DOCNO>
	<brief_summary>This clinical trial study fludarabine phosphate , low-dose total-body irradiation , peripheral blood stem cell transplant follow donor lymphocyte infusion treat old patient chronic myeloid leukemia . Giving chemotherapy total-body irradiation donor bone marrow transplant help stop growth cancer cell . It may also stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Giving cyclosporine mycophenolate mofetil transplant may stop happen . Once donated stem cell begin work , patient 's immune system may see remain cancer cell belong patient 's body destroy ( call graft-versus-tumor effect ) . Giving infusion donor 's white blood cell ( donor lymphocyte infusion ) may boost effect .</brief_summary>
	<brief_title>Fludarabine Phosphate , Low-Dose Total-Body Irradiation , Peripheral Blood Stem Cell Transplant Followed Donor Lymphocyte Infusion Treating Older Patients With Chronic Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine mixed hematopoietic chimerism safely establish use non-myeloablative conditioning regimen patient &gt; 65 year age chronic myeloid leukemia ( CML ) chronic accelerate phase human leukocyte antigen ( HLA ) identical related donor . II . To determine mixed chimerism , establish non-myeloablative conditioning regimen , convert full donor hematopoietic chimerism infusion donor lymphocyte ( DLI ) , thereby produce immunologic cure malignancy . OUTLINE : CONDITIONING REGIMEN : Patients receive fludarabine phosphate intravenously ( IV ) day -4 -2 undergo low-dose total-body irradiation ( TBI ) day 0 . TRANSPLANTATION : Patients undergo allogeneic peripheral blood stem cell transplantation ( PBSCT ) day 0 . IMMUNOSUPPRESSION : Patients receive cyclosporine orally ( PO ) twice daily ( BID ) IV BID thrice daily ( TID ) day -3 56 taper day 77 180 , mycophenolate mofetil PO IV BID day 0-27 . DLI : At least 2 week completion immunosuppression , patient &gt; 5 % donor cluster differentiation ( CD ) 3+ T cell evidence graft-versus-host disease ( GVHD ) receive donor lymphocyte IV 30 minute . Patients may receive 3 DLIs increase cell dos absence GVHD . After completion study treatment , patient follow periodically 5 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patients Philadelphia chromosome positive ( Ph+ ) CML first second chronic first accelerated phase Patients = &lt; 65 year old high risk regimen relate toxicity preexist chronic disease affect liver , lung , and/or heart , others wish treat protocol , consider casebycase basis ; transplant approve inclusion criterion participate institution ' patient review committee Patient Care Conference ( PCC ) Fred Hutchinson Cancer Research Center ( FHCRC ) principal investigator collaborate center ; patient = &lt; 65 year age receive previous highdose transplantation require patient review committee approval ; child &lt; 12 year must discuss FHCRC principal investigator ( PI ) ( Brenda Sandmaier , MD 2066674961 ) prior registration HLA genotypically identical related donor willing undergo leukapheresis initially collection peripheral blood stem cell ( PBSC ) subsequently collection peripheral blood mononuclear cell ( PBMC ) Patients treat alpha interferon must discontinue drug least 1 month prior transplant DONOR : HLA genotypically identical family member ( exclude identical twin ) DONOR : Donor must consent filgrastim ( GCSF ) administration leukapheresis DONOR : Donor must adequate vein leukapheresis agree placement central venous catheter ( femoral , subclavian ) Patients human immunodeficiency virus positive ( HIV+ ) GROUP 1 : ( PATIENTS AGED &gt; 65 AND &lt; 75 YEARS ) Patients unwilling use contraceptive technique 12 month follow treatment Presence circulate leukemic blast ( peripheral blood ) detect standard pathology patient CML Patients interferon induce complete partial cytogenetic remission Organ dysfunction : Patients renal failure eligible , however patient renal compromise ( Serum creatinine great 2.0 ) likely compromise renal function may require hemodialysis ( may permanent ) due need maintain adequate serum cyclosporine level Cardiac ejection fraction &lt; 40 % ; ejection fraction require patient history anthracyclines history cardiac disease Diffusing capacity lung carbon monoxide ( DLCO ) &lt; 50 % predict Liver function test include total bilirubin , serum glutamic pyruvate transaminase ( SGPT ) serum glutamic oxaloacetic transaminase ( SGOT ) &gt; 2x upper limit normal unless proven due malignancy Karnofsky score &lt; 70 Patients poorly control hypertension GROUP 2 ( PATIENTS AGED = &lt; 65 ) Patients HIV+ Presence circulate leukemic blast ( peripheral blood ) detect standard pathology patient CML Females pregnant Patients unwilling use contraceptive technique 12 month follow treatment Patients interferon induce complete partial cytogenetic remission Organ dysfunction : Patients renal failure eligible , however patient renal compromise ( Serum creatinine great 2.0 ) likely compromise renal function may require hemodialysis ( may permanent ) due need maintain adequate serum cyclosporine level Cardiac ejection fraction &lt; 40 % history congestive heart failure ; ejection fraction require patient history anthracyclines history cardiac disease Severe defect pulmonary function test define pulmonary consultant ( defect currently categorize mild , moderate severe ) receive supplementary continuous oxygen ; DLCO &lt; 50 % predict Liver function test : total bilirubin &gt; 2x upper limit normal , SGPT SGOT 4x upper limit normal Karnofsky score &lt; 50 Patients poorly control hypertension DONOR : Age le 12 year DONOR : Pregnancy DONOR : Infection HIV DONOR : Inability achieve adequate venous access DONOR : Known allergy GCSF DONOR : Current serious systemic illness</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>